Qure.ai Nets Six New Indications Cleared by the FDA, Taking the Chest X-ray Crown in the Radiology AI Race
The US Food and Drug Administration (FDA) has given 510(k) class II clearance of qXR-Detect, the latest computer-assisted detection (CADe) radiography solution from global AI company Qure.ai. It powers the early identification, highlighting and categorizing of key positive findings on plain film chest X-rays to support emergency room (ER) physicians, family medicine practitioners and radiologists.
Qure.ai Secures Major Global Health Grant to Build AI-Powered Point-of-Care Ultrasound
In an effort to advance health equity and reach the people that need help most, global digital health innovator Qure.ai has received a grant from the Gates Foundation.
Qure.ai Partners With Microsoft to Increase Access to Its Lung Cancer Detection and Management Suite in the U.S.
Qure.ai, a TIME100 most influential company and global leader in digital healthcare, today announced its collaboration with Microsoft. Qure.ai will onboard its end-to-end lung cancer detection, measurement and management suite of AI-powered solutions onto the Precision Imaging Network. This will streamline deployment of Qure.ai solutions to hospitals and health systems across the USA, driving digital healthcare transformation, improved tech integrations and ultimately enhance quality of patient care.
Qure.ai Continues Pace of US Growth With 19th FDA Clearance
Qure.ai, a TIME100 most influential company and global leader in digital healthcare, today announced its latest (510) K clearance from the US Food and Drug Administration (FDA). This milestone represents ongoing momentum in Qure.ai’s USA growth strategy and highlights its ongoing ability to deliver rigorously validated solutions that integrate seamlessly into hospital and clinical workflows to enhance patient outcomes.
Global Healthcare Innovator Qure.ai Expands Executive Team With Eminent Lung Health Appointment to Accelerate Clinical Strategy
Qure.ai has appointed Dr. Javier J. Zulueta, previously Professor of Medicine at the Icahn School of Medicine at Mount Sinai in New York and Pulmonary Division Chief at Mount Sinai Morningside Hospital, to a new position of Chief Medical Officer, Pulmonology.
Qure.ai Recognized Among TIME’s 100 Most Influential Companies of 2025
Qure.ai, the world’s most widely adopted digital health innovator, has been named to TIME’s 2025 TIME100 Most Influential Companies list. Now in its fifth year, the TIME100 list highlights companies making an extraordinary global impact through innovation, ambition, and measurable success.
University Hospitals Cleveland Medical Center Activates AI for Early Lung Cancer Identification
University Hospitals Cleveland Medical Center (UH) has announced a groundbreaking collaboration with global healthcare Artificial Intelligence (AI) innovator Qure.ai to deploy chest X-ray AI, supporting earlier identification of lung cancers.
Qure.ai and Project Data Sphere Combine Big Pharma Insights with Deep AI to Drive Cancer Care Forward
In a pivotal stride toward advancing cancer care, Qure.ai, a leader in artificial intelligence (AI) solutions for medical imaging, and Project Data Sphere®, a nonprofit initiative of the CEO Roundtable on Cancer, have announced their partnership to augment tumor assessments using AI-enabled solutions for clinical trials and cancer care. The collaboration aims to increase efficiency and consistency in evaluating the effectiveness of cancer treatments, ultimately improving the quality of care for patients.
Major Milestone Met in AI-Powered Fight Against Lung Cancer
The quest to eliminate lung cancer as a global cause of death has taken a positive step forward with 1 million-milestone met of a 5-million lung health Artificial Intelligence (AI) commitment. This new proactive initiative casts a wider net to currently invisible and unprofiled global patient populations, innovating beyond traditional lung cancer screening profiles such as age and smoking history.
